These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11234474)

  • 1. [Use of new quinolones in respiratory infections].
    Sanz Moreno J; Jiménez Rodríguez A
    Rev Clin Esp; 2000 Dec; 200(12):682-4. PubMed ID: 11234474
    [No Abstract]   [Full Text] [Related]  

  • 2. [A new generation of fluoroquinolones--new possibilities for the treatment of respiratory community-acquired infections].
    Iakovlev SV
    Antibiot Khimioter; 2001; 46(6):38-42. PubMed ID: 11573324
    [No Abstract]   [Full Text] [Related]  

  • 3. Newer fluoroquinolones and the management of respiratory tract infections.
    Karchmer AW
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S15. PubMed ID: 10984322
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections.
    Blasi F; Tarsia P; Cosentini R; Cazzola M; Allegra L
    Expert Opin Investig Drugs; 2003 Jul; 12(7):1165-77. PubMed ID: 12831351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the clinical efficacy and safety of injectable quinolones in the treatment of respiratory tract infections (discussion)].
    Kohno S; Watanabe A; Mikasa K; Asano K
    Jpn J Antibiot; 2003 Apr; 56(2):93-104. PubMed ID: 12825412
    [No Abstract]   [Full Text] [Related]  

  • 6. Expanding uses of fluoroquinolones: opportunities and challenges.
    Hooper DC
    Ann Intern Med; 1998 Dec; 129(11):908-10. PubMed ID: 9867736
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of newer fluoroquinolones in lower respiratory tract infections.
    Lode H; Allewelt M
    J Antimicrob Chemother; 2002 May; 49(5):709-12. PubMed ID: 12003962
    [No Abstract]   [Full Text] [Related]  

  • 8. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment?
    Norrby SR
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():99-101. PubMed ID: 9484879
    [No Abstract]   [Full Text] [Related]  

  • 9. Respiratory fluoroquinolones: differences in the details.
    Mandell LA; Iannini PB; Tillotson GS
    Clin Infect Dis; 2004 May; 38(9):1331-2; author reply 1332-3. PubMed ID: 15127351
    [No Abstract]   [Full Text] [Related]  

  • 10. Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features.
    Blondeau JM; Hansen GT
    Expert Opin Pharmacother; 2001 Feb; 2(2):317-35. PubMed ID: 11336589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?
    Momméja-Marin H; Carbon C
    Drugs; 1999 Jun; 57(6):851-3. PubMed ID: 10400400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of newer fluoroquinolones in lower respiratory tract infections.
    Lode H; Allewelt M
    J Antimicrob Chemother; 2002 Jul; 50(1):151-4. PubMed ID: 12613473
    [No Abstract]   [Full Text] [Related]  

  • 13. New concepts in antimicrobial therapy for emergency department infections.
    Talan DA
    Ann Emerg Med; 1999 Oct; 34(4 Pt 1):503-16. PubMed ID: 10532910
    [No Abstract]   [Full Text] [Related]  

  • 14. Current issues on resistance, treatment guidelines, and the appropriate use of fluoroquinolones for respiratory tract infections.
    Bishai W
    Clin Ther; 2002 Jun; 24(6):838-50; discussion 837. PubMed ID: 12117077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug not considered a first-line agent.
    Lexchin J
    Can Fam Physician; 1998 Nov; 44():2376. PubMed ID: 9839049
    [No Abstract]   [Full Text] [Related]  

  • 16. [The role of quinolones in the treatment of community acquired pneumonia].
    Garau J
    Med Clin (Barc); 1998 Feb; 110 Suppl 1():31-5. PubMed ID: 9717158
    [No Abstract]   [Full Text] [Related]  

  • 17. Two new fluoroquinolones.
    Med Lett Drugs Ther; 1992 Jun; 34(872):58-60. PubMed ID: 1317502
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance.
    Doern GV
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):821-35. PubMed ID: 17140358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of respiratory quinolone in treatment of respiratory tract infections: focusing on gatifloxacin].
    Kohno S; Watanabe A; Matsushima T
    Jpn J Antibiot; 2002 Jun; 55(3):247-58. PubMed ID: 12199109
    [No Abstract]   [Full Text] [Related]  

  • 20. [Bacteriology in community-acquired respiratory pathology].
    Weber P
    Presse Med; 1998 Mar; 27(11):546-8. PubMed ID: 9767971
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.